about
Neuromodulators for pain management in rheumatoid arthritisNeuromodulators for pain management in rheumatoid arthritis2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling.Current considerations for the treatment of severe chronic pain: the potential for tapentadol.Management of severe neuropathic cancer pain: an illustrative case and review.Diagnosing neuropathic pain in patients with cancer: comparative analysis of recommendations in national guidelines from European countries.Managing difficult pain conditions in the cancer patient.Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study.Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats.MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.Spinal morphine but not ziconotide or gabapentin analgesia is affected by alternative splicing of voltage-gated calcium channel CaV2.2 pre-mRNA.Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one in mice.Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain.Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.Psychological defensive profile of sciatica patients with neuropathic pain and its relationship to quality of life.
P2860
Q24203885-B64E872F-1E20-402A-92F5-3E63DFE168A3Q24235149-C043F1BB-C49D-4478-8B79-BB5C121647A1Q35685828-523FB507-18B6-490C-9743-01CA72425959Q37907389-314308FA-00D3-44AB-9921-B4C47520C80BQ38002778-F3ABA70F-F03A-436D-9FB3-D0292ED9D6BFQ38070867-C7EC182C-EA3B-4764-9028-8FAF0E1FA26BQ38177185-8962329B-E2D1-4AA1-BA7A-E198D7031736Q39265946-7751BA68-FA5F-4691-883D-F69CAFEBC89DQ39965771-6EAC2609-A7BA-48A7-A31E-5FE600CFAD46Q41139755-F0FF3683-570D-42BA-9C4B-1127A8396C24Q41876986-EB88365C-5294-4E02-8ABB-19F79DA62CC9Q41997150-9B494E1A-4D1F-4B75-A4CA-250FC6FE1F95Q42817278-84338817-8BB4-4E52-A0BF-13524B9B76A8Q43005382-5FF18624-7119-4D35-A8B0-FB81DED75041Q48059666-5B084CB2-3F57-42D0-8DC4-95CDB0E6040D
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
What is new in neuropathic pain?
@ast
What is new in neuropathic pain?
@en
type
label
What is new in neuropathic pain?
@ast
What is new in neuropathic pain?
@en
prefLabel
What is new in neuropathic pain?
@ast
What is new in neuropathic pain?
@en
P2860
P1476
What is new in neuropathic pain?
@en
P2093
Mellar P Davis
P2860
P2888
P304
P356
10.1007/S00520-006-0156-0
P577
2006-11-28T00:00:00Z